TEAS RF New Application

DICERNA

Dicerna Pharmaceuticals, Inc.

Trademark/Service Mark Application, Principal Register

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1478 (Rev 09/2006)
OMB No. 0651-0009 (Exp 02/28/2021)

Trademark/Service Mark Application, Principal Register

Serial Number: 88694422
Filing Date: 11/15/2019

The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88694422
MARK INFORMATION
*MARK \\TICRS\EXPORT17\IMAGEOUT 17\886\944\88694422\xml1\ RFA0002.JPG
SPECIAL FORM YES
USPTO-GENERATED IMAGE NO
LITERAL ELEMENT DICERNA
COLOR MARK YES
COLOR(S) CLAIMED
(If applicable)
The color(s) white and blue is/are claimed as a feature of the mark.
*DESCRIPTION OF THE MARK
(and Color Location, if applicable)
The mark consists of DICERNA in stylized white letters on a blue background.
PIXEL COUNT ACCEPTABLE NO
PIXEL COUNT 310 x 163
REGISTER Principal
APPLICANT INFORMATION
*OWNER OF MARK Dicerna Pharmaceuticals, Inc.
*STREET 87 Cambridgepark Drive
*CITY Cambridge
*STATE
(Required for U.S. applicants)
Massachusetts
*COUNTRY United States
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
02140
LEGAL ENTITY INFORMATION
TYPE corporation
STATE/COUNTRY OF INCORPORATION Delaware
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS 005 
*IDENTIFICATION Pharmaceutical preparations for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies.
FILING BASIS SECTION 1(b)
INTERNATIONAL CLASS 042 
*IDENTIFICATION Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.
FILING BASIS SECTION 1(b)
ADDITIONAL STATEMENTS SECTION
ACTIVE PRIOR REGISTRATION(S) The applicant claims ownership of active prior U.S. Registration Number(s) 4624556, 4631982, and 4632017.
ATTORNEY INFORMATION
NAME Glenn A. Gundersen
ATTORNEY DOCKET NUMBER 166233-039
ATTORNEY BAR MEMBERSHIP NUMBER XXX
YEAR OF ADMISSION XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY XX
FIRM NAME Dechert LLP
STREET 2929 Arch Street, Cira Centre
CITY Philadelphia
STATE Pennsylvania
COUNTRY United States
ZIP/POSTAL CODE 19104-2808
PHONE 215-994-4000
EMAIL ADDRESS trademarks@dechert.com
AUTHORIZED TO COMMUNICATE VIA EMAIL Yes
OTHER APPOINTED ATTORNEY Gayle Denman, Spencer Joffrion, Jennifer Insley-Pruitt, Hal Borden
CORRESPONDENCE INFORMATION
NAME Glenn A. Gundersen
FIRM NAME Dechert LLP
STREET 2929 Arch Street, Cira Centre
CITY Philadelphia
STATE Pennsylvania
COUNTRY United States
ZIP/POSTAL CODE 19104-2808
PHONE 215-994-4000
*EMAIL ADDRESS trademarks@dechert.com
*AUTHORIZED TO COMMUNICATE VIA EMAIL Yes
FEE INFORMATION
APPLICATION FILING OPTION TEAS RF
NUMBER OF CLASSES 2
APPLICATION FOR REGISTRATION PER CLASS 275
*TOTAL FEE DUE 550
*TOTAL FEE PAID 550
SIGNATURE INFORMATION
SIGNATURE NOT PROVIDED
SIGNATORY'S NAME NOT PROVIDED
SIGNATORY'S POSITION NOT PROVIDED
DATE SIGNED NOT PROVIDED



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1478 (Rev 09/2006)
OMB No. 0651-0009 (Exp 02/28/2021)


Trademark/Service Mark Application, Principal Register

Serial Number: 88694422
Filing Date: 11/15/2019

To the Commissioner for Trademarks:

MARK: DICERNA (stylized and/or with design, see mark)
The literal element of the mark consists of DICERNA. The color(s) white and blue is/are claimed as a feature of the mark. The mark consists of DICERNA in stylized white letters on a blue background.
The applicant, Dicerna Pharmaceuticals, Inc., a corporation of Delaware, having an address of
      87 Cambridgepark Drive
      Cambridge, Massachusetts 02140
      United States

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  Pharmaceutical preparations for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies.
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 042:  Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.



Claim of Active Prior Registration(s)
The applicant claims ownership of active prior U.S. Registration Number(s) 4624556, 4631982, and 4632017.


The applicant hereby appoints Glenn A. Gundersen. Other appointed attorneys are Gayle Denman, Spencer Joffrion, Jennifer Insley-Pruitt, Hal Borden. Glenn A. Gundersen of Dechert LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      2929 Arch Street, Cira Centre
      Philadelphia, Pennsylvania 19104-2808
      United States
      215-994-4000(phone)
      trademarks@dechert.com (authorized).
The attorney docket/reference number is 166233-039.
Glenn A. Gundersen submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:
      Glenn A. Gundersen
      Dechert LLP
      2929 Arch Street, Cira Centre
      Philadelphia, Pennsylvania 19104-2808
      215-994-4000(phone)
      trademarks@dechert.com (authorized).

Email Authorization: I authorize the USPTO to send email correspondence concerning the application to the applicant, the applicant's attorney, or the applicant's domestic representative at the email address provided in this application. I understand that a valid email address must be maintained and that the applicant or the applicant's attorney must file the relevant subsequent application-related submissions via the Trademark Electronic Application System (TEAS). Failure to do so will result in the loss of TEAS Reduced Fee status and a requirement to submit an additional processing fee of $125 per international class of goods/services.

A fee payment in the amount of $550 has been submitted with the application, representing payment for 2 class(es).

Declaration

Declaration Signature

Signature: Not Provided    Date: Not Provided
Signatory's Name: Not Provided
Signatory's Position: Not Provided
Payment Sale Number: 88694422
Payment Accounting Date: 11/15/2019

Serial Number: 88694422
Internet Transmission Date: Fri Nov 15 15:50:32 EST 2019
TEAS Stamp: USPTO/BAS-XXX.XXX.XXX.XXX-20191115155032
653706-88694422-700efcf377253c5357cef55f
9b4b4f3dd4729b218b68cdd7137803098148927d
f-DA-50323862-20191115154915826130

TEAS RF New Application [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed